| Home | E-Submission | Sitemap | Contact Us
Korean J Intern Med > Volume 28(2); 2013 > Article
Lee: Patients treated with a tumor necrosis factor-α inhibitor are more likely to develop extrapulmonary tuberculosis
See Article on Page 174-179
Tumor necrosis factor (TNF) and TNF receptors play a key role in mediating immune responses in acute and chronic inflammation. Over the past decade, TNF inhibitors have become invaluable in the treatment of chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis and psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and inflammatory bowel disease [1]. The United States Food and Drug Administration (FDA) approved infliximab, a humanized monoclonal antibody against TNF-α, for use in patients with Crohn's disease in 1998, and in those with rheumatoid arthritis in 1999. Although only one case of tuberculosis after infliximab therapy was reported in a clinical trial [2], 70 cases were detected through the MedWatch spontaneous reporting system of the FDA within 3 years of approval [3]. Subsequent studies revealed that the relative risk for tuberculosis is increased 1.6 to 25.1 times following TNF-α inhibitor therapy, depending on the clinical setting and the TNF-α inhibitor used [1]. Therefore, recent guidelines recommend that all patients undergoing TNF-α inhibitor therapy should be screened for tuberculosis, and that patients with latent tuberculosis infection (LTBI) receive preventive chemotherapy [1].
The role of TNF-α in the human immune response to tuberculosis remains unclear. Antibodies against TNF-α caused a reactivation of tuberculosis in a mouse model of LTBI [4]. TNF-α inhibitors have been used in South Korea since 2001. Screening and preventive chemotherapy for LTBI would seem to be essential before commencing TNF-α inhibitor therapy in South Korea, a country with an intermediate tuberculosis burden. Seong et al. [5] reported that the risk of tuberculosis is 9-fold higher in Korean patients with rheumatoid arthritis and 30-fold higher in rheumatoid arthritis patients treated with infliximab, compared with the general Korean population [5]. In this report, only 193 patients treated with TNF-α inhibitors were identified, two of whom developed tuberculosis during the study period [5]. In the current issue of The Korean Journal of Internal Medicine, Chung et al. [6] described the clinical characteristics and treatment responses of seven patients with tuberculosis among 457 treated with a TNF-α inhibitor. The incidences of tuberculosis after TNF-α inhibitor therapy were not significantly different between the reports of Seong et al. [5] and Chung et al. [6] (2/193, 1.0% [95% confidence interval (CI), 0.04% to 3.9%] vs. 7/457, 1.5% [95% CI, 0.7% to 3.2%]).
According to an official report of the Korean National Tuberculosis Association (http://www.knta.or.kr), the proportion of extrapulmonary tuberculosis among newly reported cases in Korea is less than 24%. Extrapulmonary involvement was common (57%) among TNF-α inhibitor users who developed tuberculosis according to Chung et al. [6]. This finding is comparable with the results of previous studies which included TNF-α inhibitor users [3] and solid organ transplant recipients [7,8]. In data from the FDA reporting system, the majority of the patients (56%) had extrapulmonary tuberculosis, and 24% had disseminated disease [3]. These patterns are similar to those of solid organ transplant recipients. Among kidney and liver transplant recipients who developed tuberculosis, extrapulmonary involvement was common (67%), including cases of disseminated disease (27% to 31%) [7,8]. Furthermore, classic symptoms of tuberculosis, such as fever, night sweats, and weight loss, may not be present [3,7]. This unusual manifestation of tuberculosis may make diagnosis uncertain. Therefore, the diagnosis of tuberculosis requires a high index of suspicion in patients treated with TNF-α inhibitors. Diagnostic invasive procedures such as tissue biopsy or aspiration of body fluids and abscesses are often required.
In the report by Chung et al. [6], most patients were not screened for LTBI, because the study was performed before the publication of official Korean guidelines for TNF-α inhibitor users. To diagnose LTBI, all patients undergoing TNF-α inhibitor therapy should be screened for a history of untreated or inadequately treated tuberculosis, and/or for recent contact with an active tuberculosis patient. In addition to the patient history, a tuberculin skin test must be included in LTBI screening. The prevalence of LTBI, determined by a tuberculin skin test (diameter of induration, > 10 mm), is estimated to be 37% in Korean patients treated with TNF-α inhibitors [9]. The ability of the tuberculin skin test to diagnose LTBI in patients with rheumatologic disease might be suboptimal, due to anergy to skin test antigens and to the effects of immunosuppressive drugs [9]. These shortcomings of tuberculin skin tests have generated interest in interferon-γ release assays [10]. However, further studies are awaited to determine whether the ability of interferon-γ release assays for LTBI can better predict the development of tuberculosis in TNF-α inhibitor users.

Conflict of interest

No potential conflict of interest relevant to this article is reported.

References

1. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185–1206PMID : 20530046.
crossref pmid
2. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT Study Group. Lancet 1999;354:1932–1939PMID : 10622295.
crossref pmid
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–1104PMID : 11596589.
crossref pmid
4. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847–1855PMID : 11179363.
crossref pmid pmc
5. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706–711PMID : 17309133.
pmid
6. Chung KB, Lee EY, Im JP, Han SK, Yim JJ. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor. Korean J Intern Med 2013;28:174–179.
crossref pmid pmc
7. Canet E, Dantal J, Blancho G, Hourmant M, Coupel S. Tuberculosis following kidney transplantation: clinical features and outcome: a French multicentre experience in the last 20 years. Nephrol Dial Transplant 2011;26:3773–3778PMID : 21467129.
crossref pmid
8. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009;15:894–906PMID : 19642133.
crossref pmid
9. Yun JW, Lim SY, Suh GY, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007;22:779–783PMID : 17982222.
crossref pmid pmc
10. Hur JA, Seo SH, Park SH, Cho CS, Kim HY. Discrepancy between the tuberculin skin test and the T-SPOT.TB for detecting latent Mycobacterium tuberculosis infection in patients with rheumatoid arthritis. J Korean Rheum Assoc 2006;13:285–290.

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6792   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
Copyright © 2018 The Korean Association of Internal Medicine. All rights reserved.
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
powerd by m2community